Skip to main content

Advertisement

SpringerLink
Log in

Carbonic anhydrase 1 is a promising biomarker for early detection of non-small cell lung cancer

  • Original Article
  • Published:
Tumor Biology

Abstract

This study aimed to identify candidate biomarkers associated with stage I non-small cell lung cancer (NSCLC). Sera from three groups, a lung cancer group (n = 11), benign control group (n = 12), and normal control group (n = 10), were collected and pooled. Protein expression profiles were analyzed by a combination of two-dimensional electrophoresis (2DE) and matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS). These methods were used to separate, screen, and identify proteins that were differentially expressed between stage I NSCLC and controls. Differentially expressed proteins were validated by both Western blot and ELISA in an expanded sample size (22, 18, and 18 in three groups, respectively). MALDI-MS identified 12 differentially expressed proteins in the lung cancer group compared to the two control groups. Expression of carbonic anhydrase 1 (CA1) was validated by Western blot. CA1 was significantly elevated in the lung cancer group compared to controls. ELISA results confirmed that CA1 in the lung cancer group (3.18 ± 1.27 ng/mL, n = 22) was highly expressed in stage I NSCLC patients compared to those in the benign control group (2.21 ± 0.71 ng/mL, n = 18) and the normal control group (2.04 ± 0.63 ng/mL, n = 18) (P = 0.001). In conclusion, we provide evidence that CA1 is highly expressed in the sera of stage I NSCLC patients. Additionally, CA1 might serve as a novel biomarker for early detection of NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  2. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355(9202):479–85. doi:10.1016/S0140-6736(00)82038-3.

    Article  CAS  PubMed  Google Scholar 

  3. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. doi:10.1056/NEJMoa1102873.

    Article  Google Scholar 

  4. Halling KC, Rickman OB, Kipp BR, Harwood AR, Doerr CH, Jett JR. A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. Chest. 2006;130(3):694–701. doi:10.1378/chest.130.3.694.

    Article  PubMed  Google Scholar 

  5. Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med. 2007;13(3):361–6. doi:10.1038/nm1556.

    Article  CAS  PubMed  Google Scholar 

  6. Patz Jr EF, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon 2nd JE. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol. 2007;25(35):5578–83. doi:10.1200/JCO.2007.13.5392.

    Article  PubMed  Google Scholar 

  7. Pecot CV, Li M, Zhang XJ, Rajanbabu R, Calitri C, Bungum A, et al. Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. Cancer Epidemiol Biomarkers Prev. 2012;21(5):786–92. doi:10.1158/1055-9965.EPI-11-0932.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ritorto MS, Borlak J. Combined serum and tissue proteomic study applied to a c-Myc transgenic mouse model of hepatocellular carcinoma identified novel disease regulated proteins suitable for diagnosis and therapeutic intervention strategies. J Proteome Res. 2011;10(7):3012–30. doi:10.1021/pr101207t.

    Article  CAS  PubMed  Google Scholar 

  9. Zhang W, Miao J, Wang S, Zhang Y. The protective effects of beta-casomorphin-7 against glucose-induced renal oxidative stress in vivo and vitro. PLoS One. 2013;8(5):e63472. doi:10.1371/journal.pone.0063472.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Song QB, Hu WG, Wang P, Yao Y, Zeng HZ. Identification of serum biomarkers for lung cancer using magnetic bead-based SELDI-TOF-MS. Acta Pharmacol Sin. 2011;32(12):1537–42. doi:10.1038/aps.2011.137.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Jeong HC, Kim GI, Cho SH, Lee KH, Ko JJ, Yang JH, et al. Proteomic analysis of human small cell lung cancer tissues: up-regulation of coactosin-like protein-1. J Proteome Res. 2011;10(1):269–76. doi:10.1021/pr100714b.

    Article  CAS  PubMed  Google Scholar 

  12. Dowling P, O’Driscoll L, Meleady P, Henry M, Roy S, Ballot J, et al. 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis. 2007;28(23):4302–10. doi:10.1002/elps.200700246.

    Article  CAS  PubMed  Google Scholar 

  13. Albert JM, Gonzalez A, Massion PP, Chen H, Olson SJ, Shyr Y, et al. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1845–51. doi:10.1158/1055-9965.EPI-07-0146.

    Article  CAS  PubMed  Google Scholar 

  14. Zhu HF, Li J, Huang L, Yan YQ. Intrahepatic cholangiocarcinoma: a clinicopathologic study of 37 resected cases. Hepatogastroenterology. 2013;60(122):263–7. doi:10.5754/hge12711.

    CAS  PubMed  Google Scholar 

  15. Perez-Sayans M, Garcia-Garcia A, Scozzafava A, Supuran CT. Inhibition of V-ATPase and carbonic anhydrases as interference strategy with tumor acidification processes. Curr Pharm Des. 2012;18(10):1407–13.

    Article  CAS  PubMed  Google Scholar 

  16. Stander BA, Joubert F, Tu C, Sippel KH, McKenna R, Joubert AM. In vitro evaluation of ESE-15-ol, an estradiol analogue with nanomolar antimitotic and carbonic anhydrase inhibitory activity. PLoS One. 2012;7(12):e52205. doi:10.1371/journal.pone.0052205.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Syrjanen L, Luukkaala T, Leppilampi M, Kallioinen M, Pastorekova S, Pastorek J, et al. Expression of cancer-related carbonic anhydrases IX and XII in normal skin and skin neoplasms. APMIS. 2014;122(9):880–9. doi:10.1111/apm.12251.

    Article  PubMed  Google Scholar 

  18. Aomatsu N, Yashiro M, Kashiwagi S, Kawajiri H, Takashima T, Ohsawa M, et al. Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline. BMC Cancer. 2014;14:400. doi:10.1186/1471-2407-14-400.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Wykoff CC, Beasley N, Watson PH, Campo L, Chia SK, English R, et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol. 2001;158(3):1011–9. doi:10.1016/S0002-9440(10)64048-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Adams A, van Brussel AS, Vermeulen JF, Mali WP, van der Wall E, van Diest PJ, et al. The potential of hypoxia markers as target for breast molecular imaging—a systematic review and meta-analysis of human marker expression. BMC Cancer. 2013;13:538. doi:10.1186/1471-2407-13-538.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Unwin RD, Harnden P, Pappin D, Rahman D, Whelan P, Craven RA, et al. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics. 2003;3(1):45–55. doi:10.1002/pmic.200390008.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Tianjin Chest Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Author information

Authors and Affiliations

  1. Department of Cardiothoracic Surgery, Tianjin Hospital, 406 Jiefang South Road, Hexi District, Tianjin, 300211, China

    Dong-bin Wang

  2. Department of Thoracic Surgery, Tianjin Chest Hospital, Tianjin, 300222, China

    Xi-ke Lu & Xun Zhang

  3. Department of Thoracic Surgery, Tianjin Nankai Hospital, Tianjin, 300100, China

    Zhi-gang Li & Cai-xia Li

Authors
  1. Dong-bin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xi-ke Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhi-gang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cai-xia Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dong-bin Wang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Db., Lu, Xk., Zhang, X. et al. Carbonic anhydrase 1 is a promising biomarker for early detection of non-small cell lung cancer. Tumor Biol. 37, 553–559 (2016). https://doi.org/10.1007/s13277-015-3834-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3834-z

Keywords

Search

Navigation